ÂÜÀòÂÒÂ×

Daniel Quevedo, PhD, currently serves as Director of Portfolio Management at Azurity Pharmaceuticals since October 2024. Previously, Daniel held the position of Associate Director at METiS Therapeutics, where strategic realignment of the LNP technology portfolio was directed to enhance business continuity and identify growth opportunities in musculoskeletal, neurological, and pulmonary disease treatments. Daniel's experience includes serving as Senior Manager at TRINITY, specializing in gene therapy projects and corporate strategy, as well as innovating in protein engineering during a tenure as Graduate Research Assistant at the University of Michigan. Early research experiences include work as a PhD intern at BASF, a Fulbright Fellow at Karlsruher Institut für Technologie, and various research assistant roles at the University of Miami and University of Wisconsin-Madison. Academic qualifications include a PhD and MS in Biomedical/Medical Engineering from the University of Michigan and a BS in the same field from the University of Miami.